Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma.
Denileukin diftitox (DAB(389)IL-2 or Ontak) is a synthetic fusion protein with demonstrated efficacy in a number of lymphoproliferative disorders, including non-Hodgkin's lymphoma. We report the case of a 45-year-old man with progressive follicular large cell lymphoma following an autologous stem cell transplant treated with denileukin diftitox who developed a fatal skin rash associated with extensive erythema, edema and large bullae involving his entire body. The clinical features and pathology were compatible with toxic epidermal necrolysis. This is the first reported case of toxic epidermal necrolysis in the literature associated with denileukin diftitox.
Polder
Kristel
K
Memorial Hermann Hospital, University of Texas Health Science Center at Houston, TX, USA.
Wang
Chiyu
C
Duvic
Madeleine
M
Diwan
Abdul H
AH
Parks
Donald
D
Jankov
Aleksandar
A
Walker
Pamela L
PL
Tong
Ann T
AT
Bull
Joan
J
Dang
Nam H
NH
D000970:Antineoplastic Agents / Q000009:adverse effects*; D044383:Black People; D003872:Dermatitis / Q000473:pathology; D004167:Diphtheria Toxin / Q000009:adverse effects*; D017809:Fatal Outcome; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects*; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011993:Recombinant Fusion Proteins / Q000009:adverse effects; D013262:Stevens-Johnson Syndrome / Q000473:pathology*; D013781:Texas; D001741:Black or African American
D000970:Antineoplastic Agents; D004167:Diphtheria Toxin; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; C078456:denileukin diftitox